Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
|
|
Kinnate Biopharma Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Kinnate Biopharma Inc. |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/05/2023 |
4
| Williams Richard Thomas (Chief Medical Officer) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Paid exercise price by delivering 541 shares
@ $4.3, valued at
$2.3k
|
|
| 06/05/2023 |
4
| Meltz Mark A (COO General Counsel Secretary) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Paid exercise price by delivering 541 shares
@ $4.3, valued at
$2.3k
|
|
| 06/05/2023 |
4
| Krishnamohan Neha (CFO) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Paid exercise price by delivering 1,459 shares
@ $4.3, valued at
$6.3k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
4
| Tananbaum James B. (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 1,550,956 shares
@ $2.8, valued at
$4.3M
Bought 229,044 shares
@ $2.8, valued at
$641.3k
|
|
| 05/10/2023 |
4
| Foresite Capital Management IV, LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 1,550,956 shares
@ $2.8, valued at
$4.3M
Bought 229,044 shares
@ $2.8, valued at
$641.3k
|
|
| 05/10/2023 |
SC 13D/A
| Foresite Capital Fund IV, L.P. reports a 29.5% stake in Kinnate Biopharma Inc. |
| 05/08/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 83,459 shares
@ $2.75, valued at
$229.5k
Bought 312,991 shares
@ $2.75, valued at
$860.7k
Bought 83,459 shares
@ $2.75, valued at
$229.5k
Bought 490,512 shares
@ $2.82, valued at
$1.4M
Bought 490,511 shares
@ $2.82, valued at
$1.4M
|
|
| 05/08/2023 |
4
| GORDON CARL L (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 83,459 shares
@ $2.75, valued at
$229.5k
Bought 312,991 shares
@ $2.75, valued at
$860.7k
Bought 83,459 shares
@ $2.75, valued at
$229.5k
Bought 490,512 shares
@ $2.82, valued at
$1.4M
Bought 490,511 shares
@ $2.82, valued at
$1.4M
|
|
| 05/08/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 16.2% stake in Kinnate Biopharma Inc. |
| 05/02/2023 |
4
| GORDON CARL L (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 60,998 shares
@ $2.55, valued at
$155.5k
Bought 228,754 shares
@ $2.55, valued at
$583.3k
Bought 60,997 shares
@ $2.55, valued at
$155.5k
Bought 124,544 shares
@ $2.62, valued at
$326.3k
Bought 467,068 shares
@ $2.62, valued at
$1.2M
Bought 124,545 shares
@ $2.62, valued at
$326.3k
Bought 58,826 shares
@ $2.67, valued at
$157.1k
Bought 220,610 shares
@ $2.67, valued at
$589k
Bought 58,826 shares
@ $2.67, valued at
$157.1k
|
|
| 05/02/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 60,998 shares
@ $2.55, valued at
$155.5k
Bought 228,754 shares
@ $2.55, valued at
$583.3k
Bought 60,997 shares
@ $2.55, valued at
$155.5k
Bought 124,544 shares
@ $2.62, valued at
$326.3k
Bought 467,068 shares
@ $2.62, valued at
$1.2M
Bought 124,545 shares
@ $2.62, valued at
$326.3k
Bought 58,826 shares
@ $2.67, valued at
$157.1k
Bought 220,610 shares
@ $2.67, valued at
$589k
Bought 58,826 shares
@ $2.67, valued at
$157.1k
|
|
| 05/02/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.1% stake in Kinnate Biopharma Inc. |
| 04/17/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in Kinnate Biopharma Inc |
| 03/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 10.6% stake in Kinnate Biopharma Inc. |
| 02/23/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 550,000 shares
@ $0
Granted 550,000 shares
@ $0 |
|
| 02/23/2023 |
3
| OrbiMed Capital GP VIII LLC (10% Owner) has filed a Form 3 on Kinnate Biopharma Inc. |
| 02/22/2023 |
4
| GORDON CARL L (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 550,000 shares
@ $0
Granted 550,000 shares
@ $0 |
|
| 02/22/2023 |
SC 13D/A
| Foresite Capital Fund IV, L.P. reports a 25.6% stake in Kinnate Biopharma Inc. |
| 02/22/2023 |
4
| Tananbaum James B. (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Acquired 1,100,000 shares
@ $0 |
|
| 02/22/2023 |
4
| Foresite Capital Management IV, LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Acquired 1,100,000 shares
@ $0 |
|
| 02/14/2023 |
4
| Meltz Mark A (COO General Counsel Secretary) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 215,000 options to buy
@ $6.78, valued at
$1.5M
|
|
| 02/14/2023 |
4
| Williams Richard Thomas (Chief Medical Officer) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 215,000 options to buy
@ $6.78, valued at
$1.5M
|
|
| 02/14/2023 |
4
| Farzan Nima (CEO) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 750,000 options to buy
@ $6.78, valued at
$5.1M
|
|
|
|
|